-
FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials
worldpharmanews
June 29, 2020
The U.S. Food and Drug Administration launched Project Patient Voice, an initiative of the FDA’s Oncology Center of Excellence (OCE).
-
AbbVie and Genmab link for oncology collaboration
pharmatimes
June 16, 2020
AbbVie and Genmab have signed a pact to jointly develop and commercialise three of the latter's early-stage investigational bispecific antibody product candidates ...
-
Thermo Fisher, Agios Pharma to Co-develop Oncology CDx
contractpharma
June 10, 2020
To identify IDH gene mutations using Oncomine Precision Assay and the Ion Torrent Genexus System, a new sequencing solution.
-
Enhertu granted orphan drug designation in US for gastric cancer
pharmaceutical-business-review
May 28, 2020
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
-
75 percent of nanopharmaceuticals are being developed for oncology
europeanpharmaceuticalreview
April 09, 2020
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
-
Innovent, Alector Enter Oncology Alliance
contractpharma
April 01, 2020
To develop and commercialize an anti-SIRP-alpha antibody (Alector's AL008) for the treatment of oncology indications in China.
-
Insight into 2020’s clinical trials landscape
europeanpharmaceuticalreview
March 11, 2020
Oncology, industry-sponsored and a combination of the two, will account for the majority of clinical trials categories over the course of the coming year.
-
Ten drugs in pre-registration likely to be blockbusters by 2025, finds report
europeanpharmaceuticalreview
March 11, 2020
New research has found that of the drugs in the pre-registration phase, 10 are expected to become blockbusters over the next six years.
-
Verastem Oncology announces new strategic direction to advance its clinical development programmes
pharmaceutical-business-review
March 06, 2020
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer ...
-
Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology
worldpharmanews
March 05, 2020
Voluntis, a leader in digital therapeutics, and Bristol-Myers Squibb Company announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients.